

ACKNOWLEDGMENTS

Most of the original data for the USRDS are provided by the Health Care Financing Administration through an Interagency Agreement between the NIDDK/DKUHD of the National Institutes of Health and the Bureau of Data Management and Strategy of the Health Care Financing Administration.

The U.S. Renal Data System offers its most grateful appreciation to everyone who helped to make this **USRDS 1998 Annual Data Report** a reality, especially all the ESRD professionals and Networks on whose reporting of data this enterprise ultimately rests.

Lawrence Y.C. Agodoa, M.D.
USRDS Project Officer
NIH/NIDDK/DKUHD

Philip J. Held, Ph.D.
Director, USRDS Coordinating Center
University of Michigan (to 2/9/98)

Robert A. Wolfe, Ph.D.
Director, USRDS Coordinating Center
University of Michigan (effective 2/9/98)

Friedrich K. Port, M.D., M.S.
Deputy Director, USRDS Coordinating Center
University of Michigan

SUGGESTED CITATION

The suggested citation for this report is as follows:

U.S. Renal Data System, **USRDS 1998 Annual Data Report**
National Institutes of Health, National Institute of
Diabetes and Digestive and Kidney Diseases
Bethesda, MD, April 1998.

Publications based upon USRDS data reported here or supplied upon request must include the citation as noted above and the following notice:

The data reported here have been supplied by the United States Renal Data System (USRDS). The interpretation and reporting of these data are the responsibility of the author(s) and in no way should be seen as an official policy or interpretation of the U.S. Government.

The USRDS would like to thank the members of the Biomedical and Economic Scientific Advisory Committees who generously donated their time to a peer review of this 1998 Annual Data Report.

The USRDS 1998 Annual Data Report

Table of Contents

	Page
LIST OF COMMON ABBREVIATIONS.....	xi
EXECUTIVE SUMMARY.....	xv
 CHAPTERS	
I. The USRDS and Its Products	1
II. Incidence and Prevalence of ESRD	23
III. Treatment Modalities for ESRD Patients.....	37
IV. Medication Use Among Dialysis Patients in the DMMS.....	51
V. Patient Mortality and Survival	63
VI. Causes of Death	79
VII. Renal Transplantation: Access and Outcomes	91
VIII. Pediatric End-Stage Renal Disease	105
IX. Hospitalization.....	121
X. The Economic Cost of ESRD and Medicare Spending for Alternative Modalities of Treatment.....	133
XI. Annual Facility Survey of Providers of ESRD Therapy	149
XII. International Comparisons of ESRD Therapy.....	157
XIII. Analytical Methods.....	167
 REFERENCE TABLES	
TABLE OF CONTENTS AND INTRODUCTION	
A. Incidence of Reported ESRD Therapy	
B. Prevalence of Reported ESRD Therapy	
C. Methods of Treatment	
D. Mortality and Causes of Death	

- E. Patient Survival**
- F. The Kidney Transplant Process**
- G. Transplant Outcome**
- H. Hospitalization**
- I. Institutional Providers of ESRD Service**
- J. Census Population Base**
- K. Medicare Payments**

APPENDICES

A. USRDS Papers, Abstracts and Presentations

B. Selected Special Studies Data Collection Forms

Case Mix Adequacy Study

(Patient and Dialysis Facility Forms)

Administered in 1992 to HD Patients Prevalent on December 31, 1990

Pediatric Growth and Development Study

Administered in 1991 to Patients born after December 31, 1970, and treated in at least one dialysis or transplant unit for 30 consecutive days or more during 1990

Dialysis Morbidity and Mortality Study

(DMMS) Wave I

Administered in 1995 to HD Patients Prevalent on December 31, 1993

Dialysis Morbidity and Mortality Study

(DMMS) Wave II

Administered in 1996 to PD and HD Patients Incident during 1996

Dialysis Morbidity and Mortality Study

(DMMS) Wave III and Wave IV

Administered in 1996-1997 to HD Patients Prevalent on December 31, 1993

C. Research Projects Using USRDS Data